Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5741778A · kind A · utility
59Cited by
6References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 19, 1996 |
| Grant date | Apr 21, 1998 |
| Priority date | — |
| Expiry date | Mar 19, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are provided for preventing or reducing N-methyl-D-aspartate (NMDA) receptor agonist-mediated neuronal cell death by administering a glial cell line-derived neurotrophic factor (GDNF) protein product.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.